Celadon Pharmaceuticals Plc

LSE CEL.L

Celadon Pharmaceuticals Plc Price to Book Ratio (P/B) on January 14, 2025: 3.35

Celadon Pharmaceuticals Plc Price to Book Ratio (P/B) is 3.35 on January 14, 2025, a -83.47% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Celadon Pharmaceuticals Plc 52-week high Price to Book Ratio (P/B) is 24.22 on April 18, 2024, which is 623.64% above the current Price to Book Ratio (P/B).
Celadon Pharmaceuticals Plc 52-week low Price to Book Ratio (P/B) is 2.57 on December 20, 2024, which is -23.20% below the current Price to Book Ratio (P/B).
Celadon Pharmaceuticals Plc average Price to Book Ratio (P/B) for the last 52 weeks is 13.08.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

LSE: CEL.L

Celadon Pharmaceuticals Plc

CEO	Mr. James Gareth Short
IPO Date	March 31, 2022
Location	United Kingdom
Headquarters	32-33 Cowcross Street
Employees	27
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines. The company focuses on growing indoor hydroponic THC cannabis for use in medicinal products used to treat chronic pain. It also intends to conduct research into cannabinoids for use in chronic pain, as well as other conditions, such as autism and multiple sclerosis. The company was founded in 2018 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years